

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Unpublished clinical studies in pediatric emergence delirium - a cross sectional analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037346
Article Type:	Original research
Date Submitted by the Author:	29-Jan-2020
Complete List of Authors:	Meyburg, Jochen; UniversitätsKlinikum Heidelberg, Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany Ries, Markus; UniversitätsKlinikum Heidelberg, Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Paediatric intensive & critical care < ANAESTHETICS, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Paediatric intensive & critical care < INTENSIVE & CRITICAL CARE, MEDICAL ETHICS, Paediatric anaesthesia < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Unpublished clinical studies in pediatric emergence delirium – a cross sectional analysis

Jochen Meyburg, MD ¹ and Markus Ries, MD, PhD, MHSc, FCP ^{2*}

¹ Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

² Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

*Correspondence:

Prof. Markus Ries, MD PhD MHSc FCP

University Hospital Heidelberg

Center for Pediatric and Adolescent Medicine

Im Neuenheimer Feld 430

D-69120 Heidelberg

Germany

Phone: +49 6221 564002

Email: markus.ries@uni-heidelberg.de

Key words

emergence delirium, publication bias, research waste, clinical studies

Word count: 1605

Number of tables: 2

Number of figures: 4

Abstract

Objectives: Emergence delirium (ED) is a frequent and potentially serious complication of general anesthesia in children. Although there are various treatment strategies, no general management recommendations can be made. Selective reporting of study results may impair clinical decision making. We therefore analyzed whether the results of completed registered clinical studies in patients with pediatric ED are publicly available or remain unpublished.

Design: Cross sectional analysis.

Setting: ClinicalTrials.gov and ClinicalTrialsRegister.eu

Participants and outcome measures: We determined the proportion of published and unpublished studies registered at ClinicalTrials.gov and ClinicalTrialsRegister.eu that were marked as completed by September 1st 2018. The major trial and literature databases were used to search for publications. In addition, the study investigators were contacted directly.

Results: Of the 44 registered studies on pediatric ED, only 24 (54%) have been published by September 2019. Published trials contained data from n=2556 patients, whereas n=1644 patients were enrolled in unpublished trials. Median time to publication was 19 months. Studies completed in recent years were published faster, but still only 9 of 25 trials were published within 12 months after completion.

Conclusion: There is a distinct publication gap in clinical research in pediatric ED that may have an impact on meta-analyses and clinical practice.

Strengths and limitations of this study

- This study quantitates the amount of research waste in pediatric emergence delirium assessed as a) the number and b) sample sizes of published and unpublished completed clinical studies
- The precise reasons for non-publication of the studies included in this analysis remain unknown
- Strengths of findings as well as directions of individual unpublished studies remain unknown
- Study registers other than ClinicalTrials.gov and ClinicalTrialsRegister.eu were not analyzed

Funding statement:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Introduction

Emergence delirium (ED) can be a very stressful event for both patients and caregivers during general anesthesia in children. Although it may also develop in adults, ED is much more common in pediatric patients, with prevalences between 25% and 80% depending on the definition of ED ¹. Symptoms usually begin shortly after emergence from anesthesia and can be very frightening including self-inflicted injury or accidental removal of catheters and other medical devices. Although episodes of ED are usually short lived, it has been suspected that ED may be associated with long-term behavioral disturbances such as eating disorders, sleeping disorders, and separation anxiety ².

The exact pathophysiology of ED is not yet understood. However, several risk factors are known: young age, use of volatile anesthetics (especially sevoflurane), type of surgery (increased risk for otorhinolaryngeal and ophthalmological procedures), parental as well as patient anxiety, and pre-existing behavioral problems ³. Whereas anxiety and behavioral problems can be addressed by non-pharmacological interventions, most of these risk factors cannot be modified and prompt the pre- and/or perioperative administration of various medications including benzodiazepines, alpha-2-agonists, propofol, opioids, and ketamine ^{4 5}.

However, although it is evident that all of these drugs may have beneficial effects in specific settings to reduce the rates of ED, no universal recommendations can be derived from the existing literature for this very common and potentially serious complication. This is a typical situation in the treatment of pediatric patients, where many treatment decisions are still based on incomplete clinical data, and off-label use of various drugs is common. One important factor for the lack of clinical consensus data might be a publication bias. It is twice as likely that a positive outcome of an intervention is reported than a negative one ⁶. Such selective reporting

1
2
3 of positive results is likely to influence clinical decision making. We therefore
4 investigated potential publication bias and time to publication in registered clinical
5 trials on ED in children.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods

Identification of clinical trials

Two databases were assessed to identify registered clinical trials on Pediatric Emergence Delirium reported as completed: 1) the ClinicalTrials.gov database provided by the U.S. National Library of Medicine and 2) the European Union Clinical Trials Register at ClinicalTrialsRegister.eu. Search criteria were: keywords “emergence delirium” and “emergence agitation” with the query selection parameters “completed studies” and “child (0-17 years)”. Close of database was September 1st 2019. Data were downloaded for further analysis.

Search for publications of completed trials

To identify publications related to the registered and completed trials, ClinicalTrials.gov, PubMed and Google Scholar were searched for NCT number, EudraCT number, study title, principal investigator, study sponsor and keywords generated from the study title. If no respective publication was found, the principal investigators were contacted by email and/or ResearchGate and asked to provide information whether the study was published in a source not covered by PubMed or Google Scholar.

Data Analysis

The STROBE criteria (STrengthening the Reporting of OBservational studies in Epidemiology) were applied for design and analysis of this study ⁷. Data were analyzed for age and number of participants, gender, study type, study design, condition, intervention, availability of study results, completion date, publication date, sponsor and country of sponsor. Trials were categorized into eight groups according to their main research topic. Time to publication was calculated as the difference in

1
2
3 months between study completion date and publication date and. Missing data were
4
5 not imputed. All statistical analyses were performed in SPSS 20 (IBM Corporations,
6
7 Armonk, New York) using standard methods for descriptive statistics. Patients or the
8
9 public were not involved in the design, or conduct, or reporting, or dissemination
10
11 plans of our research.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Results

Publication status of studies

We identified a total of 47 studies that were reported as completed in the two trial databases. Of these, three unpublished studies were completed less than one year before close of the database. Because the U.S. Food and Drug Administration (FDA) allows a time frame of one year between completion and publication of the study as specified in the in the FDA Drug Administration Amendments Act (FDAAA) ⁸, these three studies were excluded from the analysis. Of the remaining 44 studies, 29 were published and 19 were unpublished. Nine principal investigators of the unpublished studies could not be contacted by email or the ResearchGate social network. Of the remaining ten, two replied and confirmed that the study results had not been published yet (figure 1). Publication rates considerably varied between different countries of the sponsor (table 1) and main topics of the investigations (table 2).

The numbers of published and unpublished studies for each year of study completion (2007 – 2018) is shown in figure 2. An increasing number of publications over the years can be observed as well as an increasing proportion of unpublished studies which even exceeded the number of published studies in the last three years.

Patient numbers

All studies involved both genders. Published trials contained data from n=2556 patients, whereas n=1644 patients were enrolled in unpublished trials. Median size of published trials was 90 (IQR 68-136), range 40-418, whereas median size of unpublished trials was 80 (IQR 55-100), range 22-156 participants. Of note, the number of patients enrolled in unpublished studies significantly exceeded those in published studies during the last years (figure 3).

Time to publication

Median time to publication was 19 (IQR 12-27), range 3 to 104 months. More recent studies were published faster, but still only 9 of 25 trials were published within 12 months after completion as warranted by the FDAAA (figure 4).

For peer review only

Discussion

Almost every second completed registered clinical trial on pediatric ED remains unpublished, making results from 1644 enrolled study patients unavailable for clinical decision making. Given the high prevalence of ED and its potentially serious Manifestations, this significant publication bias is both surprising and unsatisfying.

This lack of study results may directly influence clinical practice. An illustrative example is the use of dexmedetomidine. Two published studies could show a reduction of incidence and degree of ED following premedication with intranasal dexmedetomidine ^{9 10}. However, dexmedetomidine, like most potent sedatives, causes an unpleasant burning sensation when applied intranasally ¹¹. Oral application might therefore be a better choice for anxious children. One recent study showed that 1 µg per kg oral dexmedetomidine for premedication provided satisfactory sedation levels, but was not effective in preventing ED ¹². On the other hand, we identified an unpublished registered trial (NCT03357718) that used 2 µg/kg, so it is not known whether oral dexmedetomidine at higher doses might be as effective as intranasal application. Another unpublished study (NCT03171740) compared premedication with intranasal dexmedetomidine to oral midazolam. Intra- or postoperative dexmedetomidine application was investigated in five registered trials (NCT01901588, NCT03779282, NCT00857727, NCT01895023, NCT01535287) the results of which are not available (yet) to the public. Especially with regard to different doses and potential cardiocirculatory side-effects of intravenous dexmedetomidine, the data of these 482 patients would be very interesting.

Similar considerations can be made for several study topics summarized in table 2. Minimizing pain with intraoperative Fentanyl given at a mean dose of 2.5 µg/kg at the end of surgery reduced the incidence of ED in a study by Cohen et al. ¹³. However, in

1
2
3 the context of postoperative delirium in the PICU we could recently show that
4 fentanyl increases the risk for delirium in a dose-dependent way and that this could
5 probably attributed to substance-specific anticholinergic effects ¹⁴. Therefore it would
6 be very interesting to see the results of the 322 patients from the three unpublished
7 registered trials (NCT02753725, NCT03010540, NCT03062488) on intraoperative
8 fentanyl given at different doses.
9

10
11 Unfortunately, the low publication rate for studies on ED that we found in our analysis
12 is in line with other published observations. Anderson et al. recently reported that
13 only 38.3% of all completed or prematurely terminated trials registered at
14 ClinicalTrials.gov were published ¹⁵, and we came to similar conclusions when testing
15 for publication bias in fields as diverse as pediatric liver transplantation ¹⁶ or autism
16 ¹⁷. Publication of the results gathered in clinical trials involving human subjects is
17 considered an ethical imperative ¹⁸. In 2007 it became a legal obligation in the U.S. to
18 register all clinical trials in advance and publish its results within 12 months after
19 completion ⁸. Interestingly, the highest rate of unpublished study with regard to the
20 country of the investigation was found for the U.S. despite of this federal law. Timely
21 publication of the results is another issue that we investigated in our study. Only 9 of
22 the 24 published studies were published within 12 months after completion, and we
23 did not observe a trend to shorter publication intervals during recent years.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Limitations

50
51 Our study has several limitations. First, we only analyzed clinical trials that were
52 registered either at ClinicalTrials.gov or ClinicalTrialsRegister.eu., therefore some
53 studies registered in smaller national registers may have been missed. Second, our
54 analysis relies on the accuracy of data input in the respective register. Third, we can
55 only speculate about the reasons why half of the investigators chose not to publish
56
57
58
59
60

1
2
3 their results, because we did not receive respective information after contacting them
4 directly. Last, it is likely that some of the recently completed studies will be published
5 eventually, but still considerably later than the 12 months warranted by the FDAAA.
6
7
8
9
10

11 Conclusion

12
13
14 There is a distinct publication gap in clinical research in pediatric ED. Although this
15 does not call into question the results of published studies, it should raise awareness
16 that many aspects of the current treatment options are not exactly known and that
17 larger numbers of published trials are immensely helpful to either support existing
18 data or to challenge it thereby improving clinical practice. In addition, timely
19 publication of study results helps to improve patient care and avoids unnecessary
20 exposure to research if a similar research question is being investigated repeatedly.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authors' contributions

Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work: JM, MR

Drafting the work or revising it critically for important intellectual content: JM, MR

Final approval of the version to be published: JM, MR

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: JM, MR

Data sharing statement

All relevant data are in the manuscript.

Competing interests statement

JM and MR report no conflict of interest

References

1. Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. *Anesthesiology* 2004;100(5):1138-45.
2. Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. *Anesth Analg* 2004;99(6):1648-54, table of contents. doi: 10.1213/01.ANE.0000136471.36680.97
3. Dahmani S, Delivet H, Hilly J. Emergence delirium in children: an update. *Curr Opin Anaesthesiol* 2014;27(3):309-15. doi: 10.1097/ACO.0000000000000076
4. Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. *Br J Anaesth* 2017;118(3):335-43. doi: 10.1093/bja/aew477
5. Moore AD, Anghelescu DL. Emergence Delirium in Pediatric Anesthesia. *Paediatr Drugs* 2017;19(1):11-20. doi: 10.1007/s40272-016-0201-5
6. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;14(8):iii, ix-xi, 1-193. doi: 10.3310/hta14080
7. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12(12):1500-24. doi: 10.1016/j.ijsu.2014.07.014
8. FDAAA. Sec. 801. Expanded clinical trial registry data bank 2007 2007 [Available from: <https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82>, accessed 24 January 2020.
9. Yao Y, Qian B, Lin Y, et al. Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial. *Paediatr Anaesth* 2015;25(5):492-8. doi: 10.1111/pan.12574
10. Mukherjee A, Das A, Basunia SR, et al. Emergence agitation prevention in paediatric ambulatory surgery: A comparison between intranasal Dexmedetomidine and Clonidine. *J Res Pharm Pract* 2015;4(1):24-30. doi: 10.4103/2279-042X.150051
11. Lee Y, Kim J, Kim S, et al. Intranasal administration of dexmedetomidine (DEX) as a premedication for pediatric patients undergoing general anesthesia for dental treatment. *J Dent Anesth Pain Med* 2016;16(1):25-29. doi: 10.17245/jdapm.2016.16.1.25
12. Keles S, Kocaturk O. The Effect of Oral Dexmedetomidine Premedication on Preoperative Cooperation and Emergence Delirium in Children Undergoing Dental Procedures. *Biomed Res Int* 2017;2017:6742183. doi: 10.1155/2017/6742183
13. Cohen IT, Hannallah RS, Hummer KA. The incidence of emergence agitation associated with desflurane anesthesia in children is reduced by fentanyl. *Anesth Analg* 2001;93(1):88-91. doi: 10.1097/00000539-200107000-00019
14. Meyburg J, Dill ML, von Haken R, et al. Risk Factors for the Development of Postoperative Delirium in Pediatric Intensive Care Patients. *Pediatr Crit Care Med* 2018;19(10):e514-e21.
15. Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at ClinicalTrials.gov. *N Engl J Med* 2015;372(11):1031-9. doi: 10.1056/NEJMsa1409364

16. Breil T, Wenning D, Teufel U, et al. An Assessment of Publication Status of Pediatric Liver Transplantation Studies. *PLoS One* 2016;11(12):e0168251. doi: 10.1371/journal.pone.0168251
17. Mechler K, Hoffmann GF, Dittmann RW, et al. Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysis. *Int J Methods Psychiatr Res* 2017;26(4) doi: 10.1002/mpr.1546
18. Pearn J. Publication: an ethical imperative. *BMJ* 1995;310(6990):1313-5. doi: 10.1136/bmj.310.6990.1313

For peer review only

1
2
3 **Figure legends**
4
5
6

7 Figure 1: Flowsheet: details of the study selection process
8
9

10 Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of
11 completion
12
13
14

15 Figure 3: Distribution of patient count stratified by publication status and year
16
17

18 Figure 4: Time to publication (time between completion of the trial and publication
19 of results) in months by year of completion
20
21
22

23
24
25 “FDAAA” = timeline mandated by the U.S. Food and Drug
26 Administration Amendments Act of 2007
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Published (n=25) and unpublished (n=19) completed studies on pediatric emergence delirium by country

Countries	Published studies (n)	Unpublished studies (n)
Belgium	2	0
Brasil	0	1
Canada	1	0
China	0	2
Egypt	1	0
Greece	1	0
India	1	1
Italy	1	0
Kenya	0	1
South Korea	8	4
Thailand	2	1
Turkey	3	2
United States	4	8

Table 2: Publication status of studies registered as completed on ClinicalTrials.gov and ClinicalTrialsRegister.eu involving children with emergence delirium

Issue	Overall number of studies	Number and percentage of published studies	Number of patients enrolled in unpublished studies
Dexmedetomidin	13	5 (38%)	599
Diagnostic criteria	6	2 (33%)	326
Non-pharmacological interventions	5	4 (80%)	106
Opioids	5	2 (40%)	322
Other drugs	5	4 (80%)	66
Propofol	4	3 (75%)	100
Volatile anesthetics	3	1 (33%)	132
Midazolam	3	3 (100%)	0




Figure 1: Flowsheet: details of the study selection process

190x275mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of completion

296x209mm (300 x 300 DPI)




Figure 3: Distribution of patient count stratified by publication status and year

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4: Time to publication (time between completion of the trial and publication of results) in months by year of completion
"FDAAA" = timeline mandated by the U.S. Food and Drug Administration Amendments Act of 2007

296x209mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract – done (b) Provide in the abstract an informative and balanced summary of what was done and what was found – done
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported - done
Objectives	3	State specific objectives, including any prespecified hypotheses - done
Methods		
Study design	4	Present key elements of study design early in the paper - done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants - done
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable - done
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group - done
Bias	9	Describe any efforts to address potential sources of bias - done
Study size	10	Explain how the study size was arrived at - done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why - done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding - done (b) Describe any methods used to examine subgroups and interactions - done (c) Explain how missing data were addressed - done (d) If applicable, describe analytical methods taking account of sampling strategy – not applicable (e) Describe any sensitivity analyses – not applicable
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed - done (b) Give reasons for non-participation at each stage - done (c) Consider use of a flow diagram – done (Fig 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders - done (b) Indicate number of participants with missing data for each variable of interest – not applicable
Outcome data	15*	Report numbers of outcome events or summary measures -done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included - done

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(b) Report category boundaries when continuous variables were categorized – not applicable

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period – not applicable

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses – done
Discussion		
Key results	18	Summarise key results with reference to study objectives – done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence - done
Generalisability	21	Discuss the generalisability (external validity) of the study results – done
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based - done

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Publication bias in pediatric emergence delirium: almost half of registered clinical trials are not published

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037346.R1
Article Type:	Original research
Date Submitted by the Author:	06-Aug-2020
Complete List of Authors:	Meyburg, Jochen; UniversitätsKlinikum Heidelberg, Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany Ries, Markus; UniversitätsKlinikum Heidelberg, Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Anaesthesia
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Paediatric intensive & critical care < ANAESTHETICS, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Paediatric intensive & critical care < INTENSIVE & CRITICAL CARE, MEDICAL ETHICS, Paediatric anaesthesia < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Publication bias in pediatric emergence delirium:**
2 **almost half of registered clinical trials are not published**

3
4
5
6
7
8
9
10 Jochen Meyburg, MD ¹ and Markus Ries, MD, PhD, MHSc, FCP ^{2*}

11
12
13 ¹ Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric
14 and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

15
16 ² Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric
17 and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

18
19
20
21

22 *Correspondence:

23 Prof. Markus Ries, MD PhD MHSc FCP

24 University Hospital Heidelberg

25 Center for Pediatric and Adolescent Medicine

26 Im Neuenheimer Feld 430

27 D-69120 Heidelberg

28 Germany

29 Phone: +49 6221 564002

30 Email: markus.ries@uni-heidelberg.de

31
32
33
34
35
36
37
38

39 Key words

40 emergence delirium, publication bias, research waste, clinical studies

41
42
43
44

45 Word count: 1713

46 Number of tables: 2

47 Number of figures: 4

48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 27 **Abstract**
4

5 28 Objectives: Emergence delirium (ED) is a frequent and potentially serious complication
6
7
8 29 of general anesthesia in children. Although there are various treatment strategies, no
9
10 30 general management recommendations can be made. Selective reporting of study
11
12 31 results may impair clinical decision making. We therefore analyzed whether the results
13
14 32 of completed registered clinical studies in patients with pediatric ED are publicly
15
16 33 available or remain unpublished.

17
18
19 34 Design: Cross sectional analysis.
20

21 35 Setting: ClinicalTrials.gov and ClinicalTrialsRegister.eu
22

23 36 Participants and outcome measures: We determined the proportion of published and
24
25 37 unpublished studies registered at ClinicalTrials.gov and ClinicalTrialsRegister.eu that
26
27 38 were marked as completed by September 1st 2018. The major trial and literature
28
29 39 databases were used to search for publications. In addition, the study investigators
30
31 40 were contacted directly. For published trials, time to publication was calculated as the
32
33 41 difference in months between study completion date and publication date.
34
35

36 42 Results: Of the 44 registered studies on pediatric ED, only 24 (54%) have been
37
38 43 published by September 2019. Published trials contained data from n=2556 patients,
39
40 44 whereas n=1644 patients were enrolled in unpublished trials. Median time to
41
42 45 publication was 19 months. Studies completed in recent years were published faster,
43
44 46 but still only 9 of 25 trials were published within 12 months after completion.
45
46

47 47 Conclusion: There is a distinct publication gap in clinical research in pediatric ED that
48
49 48 may have an impact on meta-analyses and clinical practice.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 49 **Strengths and limitations of this study**
4

- 5 50 • This study quantitates the amount of research waste in pediatric emergence
6
7 delirium assessed as a) the number and b) sample sizes of published and
8 51
9 unpublished completed clinical studies
10 52
11
12 53 • The precise reasons for non-publication of the studies included in this analysis
13
14 remain unknown
15 54
16
17 55 • Strengths of findings as well as directions of individual unpublished studies
18
19 remain unknown
20 56
21
22 57 • Study registers other than ClinicalTrials.gov and ClinicalTrialsRegister.eu were
23
24 not analyzed
25 58
26
27 59

28
29 60 **Funding statement:**

30
31 61 This research received no specific grant from any funding agency in the public,
32
33 62 commercial or not-for-profit sectors.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

63 **Introduction**

64 Emergence delirium (ED) can be a very stressful event for both patients and caregivers
65 during general anesthesia in children. Although it may also develop in adults, ED is
66 much more common in pediatric patients, with prevalences between 25% and 80%
67 depending on the definition of ED ¹. Symptoms usually begin shortly after emergence
68 from anesthesia and can be very frightening including self-inflicted injury or accidental
69 removal of catheters and other medical devices. Although episodes of ED are usually
70 short lived, it has been suspected that ED may be associated with long-term behavioral
71 disturbances such as eating disorders, sleeping disorders, and separation anxiety ².
72 The exact pathophysiology of ED is not yet understood. However, several risk factors
73 are known: young age, use of volatile anesthetics (especially sevoflurane), type of
74 surgery (increased risk for otorhinolaryngeal and ophthalmological procedures),
75 parental as well as patient anxiety, and pre-existing behavioral problems ³. Whereas
76 anxiety and behavioral problems can be addressed by non-pharmacological
77 interventions, most of these risk factors cannot be modified and prompt the pre- and/or
78 perioperative administration of various medications including benzodiazepines, alpha-
79 2-agonists, propofol, opioids, and ketamine ^{4 5}.
80 However, although it is evident that all of these drugs may have beneficial effects in
81 specific settings to reduce the rates of ED, no universal recommendations can be
82 derived from the existing literature for this very common and potentially serious
83 complication. This is a typical situation in the treatment of pediatric patients, where
84 many treatment decisions are still based on incomplete clinical data, and off-label use
85 of various drugs is common. One important factor for the lack of clinical consensus
86 data might be a publication bias. It is twice as likely that a positive outcome of an
87 intervention is reported than a negative one ⁶. Such selective reporting of positive
88 results is likely to influence clinical decision making. We therefore investigated

1
2
3 89 potential publication bias and time to publication in registered clinical trials on ED in
4
5 90 children. This is a cross-sectional study.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

91 **Methods**

92 Identification of clinical trials

93 Two databases were assessed to identify registered clinical trials on Pediatric
94 Emergence Delirium reported as completed: 1) the ClinicalTrials.gov database
95 provided by the U.S. National Library of Medicine and 2) the European Union Clinical
96 Trials Register at ClinicalTrialsRegister.eu. Search criteria were: keywords
97 “emergence delirium” and “emergence agitation” with the query selection parameters
98 “completed studies” and “child (0-17 years)”. Close of database was September 1st
99 2019. Data were downloaded for further analysis.

100

101 Search for publications of completed trials

102 To identify publications related to the registered and completed trials,
103 ClinicalTrials.gov, PubMed and Google Scholar were searched for NCT number,
104 EudraCT number, study title, principal investigator, study sponsor and keywords
105 generated from the study title. If no respective publication was found, the principal
106 investigators were contacted by email and/or ResearchGate and asked to provide
107 information whether the study was published in a source not covered by PubMed or
108 Google Scholar. The authors were contacted once more if they did not reply within four
109 weeks.

110

111 Data Analysis

112 The STROBE criteria (STrengthening the Reporting of OBservational studies in
113 Epidemiology) were applied for design and analysis of this study ⁷. In order to analyze
114 characteristics of published and unpublished clinical studies in pediatric emergence
115 delirium, the following variables were analyzed: age, condition, number of participants
116 (study population), condition and intervention (topic of investigation), availability of

1
2
3 117 study results (publication status), completion date, and publication date (time-to-
4
5 118 publication), and country of sponsor (study localization). Trials were categorized into
6
7 119 eight groups according to their main research topic. Time to publication was calculated
8
9 120 as the difference in months between study completion date and publication date and.
10
11 121 Missing data were not imputed. All statistical analyses were performed in SPSS 20
12
13 122 (IBM Corporations, Armonk, New York) using standard methods for descriptive
14
15 123 statistics. No sensitivity analyses were conducted
16
17
18
19
20

21
22

23
24 125 Patient and Public involvement:

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
No patient involved

128 **Results**

129 Publication status of studies

130 We identified a total of 47 studies that were reported as completed in the two trial
131 databases. Of these, three unpublished studies were completed less than one year
132 before close of the database. Because the U.S. Food and Drug Administration (FDA)
133 allows a time frame of one year between completion and publication of the study as
134 specified in the in the FDA Drug Administration Amendments Act (FDAAA) ⁸, these
135 three studies were excluded from the analysis. Of the remaining 44 studies, 29 were
136 published and 19 were unpublished. Nine principal investigators of the unpublished
137 studies could not be contacted by email or the ResearchGate social network. Of the
138 remaining ten, two replied and confirmed that the study results had not been published
139 yet (figure 1). Publication rates considerably varied between different countries of the
140 sponsor (table 1) and main topics of the investigations (table 2).

141 The numbers of published and unpublished studies for each year of study completion
142 (2007 – 2018) is shown in figure 2. An increasing number of publications over the years
143 can be observed as well as an increasing proportion of unpublished studies which even
144 exceeded the number of published studies in the last three years.

146 Patient numbers

147 All studies involved both genders. Published trials contained data from n=2556
148 patients, whereas n=1644 patients were enrolled in unpublished trials. Median size of
149 published trials was 90 (IQR 68-136), range 40-418, whereas median size of
150 unpublished trials was 80 (IQR 55-100), range 22-156 participants. Of note, the
151 number of patients enrolled in unpublished studies significantly exceeded those in
152 published studies during the last years (figure 3).

153

1
2
3 154 Time to publication
4

5 155 Median time to publication was 19 (IQR 12-27), range 3 to 104 months. More recent
6
7 156 studies were published faster, but still only 9 of 25 trials were published within 12
8
9 157 months after completion as warranted by the FDAAA (figure 4).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

158 **Discussion**

159 Almost every second completed registered clinical trial on pediatric ED remains
160 unpublished, making results from 1644 enrolled study patients unavailable for clinical
161 decision making. Given the high prevalence of ED and its potentially serious
162 Manifestations, this significant publication bias is both surprising and unsatisfying.
163 This lack of study results may directly influence clinical practice. An illustrative example
164 is the use of dexmedetomidine. Two published studies could show a reduction of
165 incidence and degree of ED following premedication with intranasal dexmedetomidine
166 ^{9 10}. However, dexmedetomidine, like most potent sedatives, causes an unpleasant
167 burning sensation when applied intranasally ¹¹. Oral application might therefore be a
168 better choice for anxious children. One recent study showed that 1 µg per kg oral
169 dexmedetomidine for premedication provided satisfactory sedation levels, but was not
170 effective in preventing ED ¹². On the other hand, we identified an unpublished
171 registered trial (NCT03357718) that used 2 µg/kg, so it is not known whether oral
172 dexmedetomidine at higher doses might be as effective as intranasal application. For
173 three of the 19 unpublished studies, preliminary results are available at
174 ClinicalTrials.gov, and all three studies compared dexmedetomidine to placebo.
175 However, their preliminary results are as conflicting as the published ones: no positive
176 effects of intramuscular (NCT01535287) and intravenous (NCT01901588)
177 dexmedetomidine, respectively, but reduction of ED when 8-fold higher intravenous
178 doses had been used (NCT00857727). Another unpublished study (NCT03171740)
179 compared premedication with intranasal dexmedetomidine to oral midazolam. Intra- or
180 postoperative dexmedetomidine application was investigated in five registered trials
181 (NCT01901588, NCT03779282, NCT00857727, NCT01895023, NCT01535287) the
182 results of which are not available (yet) to the public. Especially with regard to different

183 doses and potential cardiocirculatory side-effects of intravenous dexmedetomidine, the
184 data of these 482 patients would be very interesting.

185 Similar considerations can be made for several study topics summarized in table 2.
186 Minimizing pain with intraoperative Fentanyl given at a mean dose of 2.5 µg/kg at the
187 end of surgery reduced the incidence of ED in a study by Cohen et al. ¹³. However, in
188 the context of postoperative delirium in the PICU we could recently show that fentanyl
189 increases the risk for delirium in a dose-dependent way and that this could probably
190 attributed to substance-specific anticholinergic effects ¹⁴. Therefore it would be very
191 interesting to see the results of the 322 patients from the three unpublished registered
192 trials (NCT02753725, NCT03010540, NCT03062488) on intraoperative fentanyl given
193 at different doses.

194 Unfortunately, the low publication rate for studies on ED that we found in our analysis
195 is in line with other published observations. Anderson et al. recently reported that only
196 38.3% of all completed or prematurely terminated trials registered at ClinicalTrials.gov
197 were published ¹⁵, and we came to similar conclusions when testing for publication
198 bias in fields as diverse as pediatric liver transplantation ¹⁶ or autism ¹⁷. Publication of
199 the results gathered in clinical trials involving human subjects is considered an ethical
200 imperative ¹⁸. In 2007 it became a legal obligation in the U.S. to register all clinical trials
201 in advance and publish its results within 12 months after completion ⁸. Interestingly,
202 the highest rate of unpublished study with regard to the country of the investigation
203 was found for the U.S. despite of this federal law. Timely publication of the results is
204 another issue that we investigated in our study. Only 9 of the 24 published studies
205 were published within 12 months after completion, and we did not observe a trend to
206 shorter publication intervals during recent years.

207

208 Limitations

1
2
3 209 Our study has several limitations. First, we only analyzed clinical trials that were
4
5 210 registered either at ClinicalTrials.gov or ClinicalTrialsRegister.eu., therefore some
6
7 211 studies registered in smaller national registers may have been missed. Second, our
8
9 212 analysis relies on the accuracy of data input in the respective register. Third, we can
10
11 213 only speculate about the reasons why half of the investigators chose not to publish
12
13 214 their results, because we did not receive respective information after contacting them
14
15 215 directly. Last, it is likely that some of the recently completed studies will be published
16
17 216 eventually, but still considerably later than the 12 months warranted by the FDAAA.
18
19
20
21
22

217

218 Conclusion

219 There is a distinct publication gap in clinical research in pediatric ED. Although this
220 does not call into question the results of published studies, it should raise awareness
221 that many aspects of the current treatment options are not exactly known and that
222 larger numbers of published trials are immensely helpful to either support existing data
223 or to challenge it thereby improving clinical practice. In addition, timely publication of
224 study results helps to improve patient care and avoids unnecessary exposure to
225 research if a similar research question is being investigated repeatedly.

1
2
3 226 ***Authors' contributions***
4

5 227 Substantial contributions to the conception or design of the work; or the acquisition,
6
7 228 analysis, or interpretation of data for the work: JM, MR
9

10 229
11
12 230 Drafting the work or revising it critically for important intellectual content: JM, MR
13

14 231
15
16 232 Final approval of the version to be published: JM, MR
17
18

19 233
20
21 234 Agreement to be accountable for all aspects of the work in ensuring that questions
22
23 235 related to the accuracy or integrity of any part of the work are appropriately investigated
24
25 236 and resolved: JM, MR
26
27

28 237
29
30 238 ***Data sharing statement***
31

32 239 All relevant data are in the manuscript.
33
34

35 240
36
37 241 ***Competing interests statement***
38

39 242 JM and MR report no conflict of interest.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

243 **References**

1. Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. *Anesthesiology* 2004;100(5):1138-45.
2. Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. *Anesth Analg* 2004;99(6):1648-54, table of contents. doi: 10.1213/01.ANE.0000136471.36680.97
3. Dahmani S, Delivet H, Hilly J. Emergence delirium in children: an update. *Curr Opin Anaesthesiol* 2014;27(3):309-15. doi: 10.1097/ACO.0000000000000076
4. Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. *Br J Anaesth* 2017;118(3):335-43. doi: 10.1093/bja/aew477
5. Moore AD, Anghelescu DL. Emergence Delirium in Pediatric Anesthesia. *Paediatr Drugs* 2017;19(1):11-20. doi: 10.1007/s40272-016-0201-5
6. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;14(8):iii, ix-xi, 1-193. doi: 10.3310/hta14080
7. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12(12):1500-24. doi: 10.1016/j.ijsu.2014.07.014
8. FDAAA. Sec. 801. Expanded clinical trial registry data bank 2007 2007 [Available from: <https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82>, accessed 24 January 2020.
9. Yao Y, Qian B, Lin Y, et al. Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial. *Paediatr Anaesth* 2015;25(5):492-8. doi: 10.1111/pan.12574
10. Mukherjee A, Das A, Basunia SR, et al. Emergence agitation prevention in paediatric ambulatory surgery: A comparison between intranasal Dexmedetomidine and Clonidine. *J Res Pharm Pract* 2015;4(1):24-30. doi: 10.4103/2279-042X.150051
11. Lee Y, Kim J, Kim S, et al. Intranasal administration of dexmedetomidine (DEX) as a premedication for pediatric patients undergoing general anesthesia for dental treatment. *J Dent Anesth Pain Med* 2016;16(1):25-29. doi: 10.17245/jdapm.2016.16.1.25
12. Keles S, Kocaturk O. The Effect of Oral Dexmedetomidine Premedication on Preoperative Cooperation and Emergence Delirium in Children Undergoing Dental Procedures. *Biomed Res Int* 2017;2017:6742183. doi: 10.1155/2017/6742183
13. Cohen IT, Hannallah RS, Hummer KA. The incidence of emergence agitation associated with desflurane anesthesia in children is reduced by fentanyl. *Anesth Analg* 2001;93(1):88-91. doi: 10.1097/00000539-200107000-00019
14. Meyburg J, Dill ML, von Haken R, et al. Risk Factors for the Development of Postoperative Delirium in Pediatric Intensive Care Patients. *Pediatr Crit Care Med* 2018;19(10):e514-e21.
15. Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at ClinicalTrials.gov. *N Engl J Med* 2015;372(11):1031-9. doi: 10.1056/NEJMsa1409364

- 1
2
3 292 16. Breil T, Wenning D, Teufel U, et al. An Assessment of Publication Status of
4 293 Pediatric Liver Transplantation Studies. *PLoS One* 2016;11(12):e0168251. doi:
5 294 10.1371/journal.pone.0168251
6 295 17. Mechler K, Hoffmann GF, Dittmann RW, et al. Defining the hidden evidence in
7 296 autism research. Forty per cent of rigorously designed clinical trials remain
8 297 unpublished - a cross-sectional analysis. *Int J Methods Psychiatr Res*
9 298 2017;26(4) doi: 10.1002/mpr.1546
10 299 18. Pearn J. Publication: an ethical imperative. *BMJ* 1995;310(6990):1313-5. doi:
11 300 10.1136/bmj.310.6990.1313
12 301
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 302 **Figure legends**
4

5 303

6
7 304 Figure 1: Flowsheet: details of the study selection process
8
9

10
11 305 Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of
12
13 306 completion
14
15

16 307 Figure 3: Distribution of patient count stratified by publication status and year
17
18

19 308 Figure 4: Time to publication (time between completion of the trial and publication
20
21
22 309 of results) in months by year of completion
23
24

25 310 "FDAAA" = timeline mandated by the U.S. Food and Drug Administration
26
27

28 311 Amendments Act of 2007
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Published (n=25) and unpublished (n=19) completed studies on pediatric emergence delirium by country

Countries	Published studies (n)	Unpublished studies (n)
Belgium	2	0
Brasil	0	1
Canada	1	0
China	0	2
Egypt	1	0
Greece	1	0
India	1	1
Italy	1	0
Kenya	0	1
South Korea	8	4
Thailand	2	1
Turkey	3	2
United States	4	8

Table 2: Publication status of studies registered as completed on ClinicalTrials.gov and ClinicalTrialsRegister.eu involving children with emergence delirium

Topic of investigation	Overall number of studies	Number and percentage of published studies	Number of patients enrolled in unpublished studies
Dexmedetomidin	13	5 (38%)	598
Diagnostic criteria	6	2 (33%)	326
Non-pharmacological interventions	5	4 (80%)	100
Opioids	5	2 (40%)	322
Other drugs	5	4 (80%)	60
Propofol	4	3 (75%)	108
Volatile anesthetics	3	1 (33%)	152
Midazolam	3	3 (100%)	0




Figure 1: Flowsheet: details of the study selection process

190x275mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of completion

296x209mm (300 x 300 DPI)




Figure 3: Distribution of patient count stratified by publication status and year

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4: Time to publication (time between completion of the trial and publication of results) in months by year of completion
"FDAAA" = timeline mandated by the U.S. Food and Drug Administration Amendments Act of 2007

296x209mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2, line 34
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2, lines 27-48
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4, line 63 to page 5 line 90
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 2, lines 28-33 Page 4, line 88 to page 5 line 90
Methods			
Study design	4	Present key elements of study design early in the paper	Page 2 line 34, page 5 line 89
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6 lines 91-109
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Page 6 lines 111-118
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 6 lines 111-118
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6 lines 91-109
Bias	9	Describe any efforts to address potential sources of bias	Page 6 lines 105-109
Study size	10	Explain how the study size was arrived at	Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 6 line 113 to page 7 line 123
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 7 lines 122-123
		(b) Describe any methods used to examine subgroups and interactions	No applicable

		(c) Explain how missing data were addressed	Page 7 line 121
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Page 7 line 123
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 8, lines 130-140, Figure 1
		(b) Give reasons for non-participation at each stage	Page 8 line 136 -139
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables 1 and 2, Figures 2 and 3
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Tables 1 and 2, Figures 2,3, and 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Not applicable
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 10 lines 159-162
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11 line 208 to page 12 line 216
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 12 lines 194 to 206
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 12 lines 219 to 225
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 3 lines 60-62

1
2
3 *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
4
5

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
7 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
8 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

BMJ Open

Publication bias in pediatric emergence delirium – a cross-sectional analysis of ClinicalTrials.gov and ClinicalTrialsRegister.eu

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037346.R2
Article Type:	Original research
Date Submitted by the Author:	26-Sep-2020
Complete List of Authors:	Meyburg, Jochen; UniversitätsKlinikum Heidelberg, Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany Ries, Markus; UniversitätsKlinikum Heidelberg, Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Anaesthesia
Keywords:	Paediatric anaesthesia < ANAESTHETICS, Paediatric intensive & critical care < ANAESTHETICS, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Paediatric intensive & critical care < INTENSIVE & CRITICAL CARE, MEDICAL ETHICS, Paediatric anaesthesia < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Publication bias in pediatric emergence delirium – a cross-**
2 **sectional analysis of ClinicalTrials.gov and ClinicalTrialsRegister.eu**

3 Jochen Meyburg, MD ¹ and Markus Ries, MD, PhD, MHSc, FCP ^{2*}

4
5 ¹ Department of General Pediatrics and Pediatric Intensive Care, Center for Pediatric
6 and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

7 ² Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric
8 and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

9
10 *Correspondence:

11 Prof. Markus Ries, MD PhD MHSc FCP

12 University Hospital Heidelberg

13 Center for Pediatric and Adolescent Medicine

14 Im Neuenheimer Feld 430

15 D-69120 Heidelberg

16 Germany

17 Phone: +49 6221 564002

18 Email: markus.ries@uni-heidelberg.de

19
20 Key words

21 emergence delirium, publication bias, research waste, clinical studies

22
23 Word count: 1872

24 Number of tables: 2

25 Number of figures: 4

1
2
3 26 **Abstract**
4

5 27 Objectives: Emergence delirium (ED) is a frequent and potentially serious complication
6
7
8 28 of general anesthesia in children. Although there are various treatment strategies, no
9
10 29 general management recommendations can be made. Selective reporting of study
11
12 30 results may impair clinical decision making. We, therefore, analyzed whether the
13
14 31 results of completed registered clinical studies in patients with pediatric ED are publicly
15
16 32 available or remain unpublished.

17
18
19 33 Design: Cross-sectional analysis.
20

21 34 Setting: ClinicalTrials.gov and ClinicalTrialsRegister.eu
22

23
24 35 Participants and outcome measures: We determined the proportion of published and
25
26 36 unpublished studies registered at ClinicalTrials.gov and ClinicalTrialsRegister.eu that
27
28 37 were marked as completed by September 1st 2018. The major trial and literature
29
30 38 databases were used to search for publications. In addition, the study investigators
31
32 39 were contacted directly. For published trials, time to publication was calculated as the
33
34 40 difference in months between study completion date and publication date.
35

36
37 41 Results: Of the 44 registered studies on pediatric ED, only 24 (54%) were published
38
39 42 by September 2019. Published trials contained data from n=2556 patients, whereas
40
41 43 n=1644 patients were enrolled in unpublished trials. Median time to publication was 19
42
43 44 months. Studies completed in recent years were published faster, but still only 9 of 25
44
45 45 trials were published within 12 months of completion.
46
47

48
49 46 Conclusion: There is a distinct publication gap in clinical research in pediatric ED that
50
51 47 may have an impact on meta-analyses and clinical practice.
52
53
54
55
56
57
58
59
60

1
2
3 48 **Strengths and limitations of this study**
4

- 5 49 • This study quantitates the amount of research waste in pediatric emergence
6 delirium assessed as a) the number and b) sample sizes of published and
7 unpublished completed clinical studies
8 50
9 51
10 52 • The precise reasons for non-publication of the studies included in this analysis
11 remain unknown
12 53
13 54 • Strengths of findings as well as directions of individual unpublished studies
14 remain unknown
15 55
16 56 • Study registers other than ClinicalTrials.gov and ClinicalTrialsRegister.eu were
17 not analyzed
18 57
19 58

20
21
22
23
24
25
26
27
28 59 **Funding statement:**

29
30
31 60 This research received no specific grant from any funding agency in the public,
32 commercial or not-for-profit sectors.
33 61
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

62 **Introduction**

63 Emergence delirium (ED) can be a very stressful event for both patients and caregivers
64 during general anesthesia in children. Although it may also develop in adults, ED is
65 much more common in pediatric patients, with prevalences between 25% and 80%
66 depending on the definition of ED ¹. Symptoms usually begin shortly after emergence
67 from anesthesia and can be very frightening including self-inflicted injury or accidental
68 removal of catheters and other medical devices. Although episodes of ED are usually
69 short lived, it has been suspected that ED may be associated with long-term behavioral
70 disturbances such as eating disorders, sleeping disorders, and separation anxiety ².
71 The exact pathophysiology of ED is not yet understood. However, several risk factors
72 are known: young age, use of volatile anesthetics (especially sevoflurane), type of
73 surgery (increased risk for otorhinolaryngeal and ophthalmological procedures),
74 parental as well as patient anxiety, and pre-existing behavioral problems ³. Whereas
75 anxiety and behavioral problems can be addressed by non-pharmacological
76 interventions, most of these risk factors cannot be modified and prompt the pre- and/or
77 perioperative administration of various medications including benzodiazepines, alpha-
78 2-agonists, propofol, opioids, and ketamine ^{4 5}.
79 However, although it is evident that all of these drugs may have beneficial effects in
80 specific settings to reduce the rates of ED, no universal recommendations can be
81 derived from the existing literature for this very common and potentially serious
82 complication. This is a typical situation in the treatment of pediatric patients, where
83 many treatment decisions are still based on incomplete clinical data, and off-label use
84 of various drugs is common. One important factor for the lack of clinical consensus
85 data might be a publication bias. It is twice as likely that a positive outcome of an
86 intervention is reported than a negative one ⁶. Such selective reporting of positive
87 results is likely to influence clinical decision making. We, therefore, investigated

1
2
3 88 potential publication bias and time to publication in registered clinical trials on ED in
4
5 89 children. This is a cross-sectional study.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

90 **Methods**

91 Purpose of this study

92 The purpose of this analysis is to characterize publication status, patient numbers,
93 topics of investigation, study localization, and time-to-publication of completed clinical
94 trials in pediatric emergence ED, with the ultimate goal to obtain an insight into
95 transparency and potential research waste in this important area of medicine.

96

97 Research reporting guideline

98 The STROBE criteria (STrengthening the Reporting of OBservational studies in
99 Epidemiology) were applied for design, analysis, and reporting of this study⁷.

100

101 Identification of clinical trials

102 Two databases were assessed to identify registered clinical trials on Pediatric ED
103 reported as completed by September 1st 2018: 1) the ClinicalTrials.gov database
104 provided by the U.S. National Library of Medicine and 2) the European Union Clinical
105 Trials Register at ClinicalTrialsRegister.eu. Search criteria were: keywords
106 “emergence delirium” and “emergence agitation” with the query selection parameters
107 “completed studies” and “child (0-17 years)”. Close of database was September 1st
108 2019. Data were downloaded for further analysis.

109

110 Search for publications of completed trials

111 To identify publications related to the registered and completed trials,
112 ClinicalTrials.gov, PubMed and Google Scholar were searched for NCT number,
113 EudraCT number, study title, principal investigator, study sponsor and keywords
114 generated from the study title. If no respective publication was found, the principal
115 investigators were contacted by email and/or ResearchGate and asked to provide

1
2
3 116 information about whether the study was published in a source not covered by PubMed
4
5 117 or Google Scholar. The authors were contacted once more if they did not reply within
6
7 118 four weeks.
8
9

10 119

12 120 Data Analysis

14 121 The following variables were analyzed: age of participants, condition, number of
16 122 participants, intervention, availability of study results, completion and publication dates
18 123 (time-to-publication), and country of sponsor. The variables “age of participants” and
20 124 “condition” refers to the inclusion criteria of a respective clinical study. Both variables
22 125 were reviewed categorially in order to ensure that only pediatric studies with patients
24 126 with emergence delirium were considered in the present analysis. The variable
26 127 “number of participants” refers to the sample size of a given clinical study. Numbers
28 128 and population sizes were calculated for both published and unpublished studies. The
30 129 variable “intervention” provided information about the main research topic of a
32 130 respective clinical study. Time-to-publication was calculated as the difference in
34 131 months between study completion date and publication date in order to ascertain when
36 132 results were made publicly available after completion of the study. The variable
38 133 “country of sponsor” provided information about the geographic localization of the
40 134 study. A detailed overview of the data is provided in the referenced supplemental table.
42 135 Trials were categorized into eight groups according to their main research topic.
44 136 Missing data were not imputed. All statistical analyses were performed in SPSS 20
46 137 (IBM Corporations, Armonk, New York) using standard methods for descriptive
48 138 statistics. No sensitivity analyses were conducted.

50 139

52 140 Patient and Public involvement:

54 141 No patient involved.
56
57
58
59
60

143 **Results**

144 Publication status of studies

145 We identified a total of 47 studies that were reported as completed in the two trial
146 databases. Of these, three unpublished studies were completed less than one year
147 before close of the database. Because the U.S. Food and Drug Administration (FDA)
148 allows a time frame of one year between completion and publication of the study as
149 specified in the FDA Drug Administration Amendments Act (FDAAA) ⁸, these three
150 studies were excluded from the analysis. Of the remaining 44 studies, 29 were
151 published and 19 were unpublished. Nine principal investigators of the unpublished
152 studies could not be contacted by email or through the ResearchGate social network.
153 Of the remaining ten, two replied and confirmed that the study results had not been
154 published yet (figure 1). Publication rates varied considerably with the country of the
155 sponsor (table 1) and the main topic of the investigation (table 2).

156 The numbers of published and unpublished studies for each year of study completion
157 (2007 – 2018) is shown in figure 2. An increasing number of publications over the years
158 can be observed as well as an increasing proportion of unpublished studies which even
159 exceeded the number of published studies in the last three years.

161 Patient numbers

162 All studies involved both genders. Published trials contained data from n=2556
163 patients, whereas n=1644 patients were enrolled in unpublished trials. Median size of
164 published trials was 90 (IQR 68-136), range 40-418, whereas median size of
165 unpublished trials was 80 (IQR 55-100), range 22-156 participants. Of note, the
166 number of patients enrolled in unpublished studies significantly exceeded those in
167 published studies during the last years (figure 3).

168

1
2
3 169 Time-to-publication
4

5 170 Median time-to-publication was 19 (IQR 12-27), range 3 to 104 months. More recent
6
7 171 studies were published faster, but still only 9 of 25 trials were published within 12
8
9 172 months after completion as warranted by the FDAAA (figure 4).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

173 **Discussion**

174 Almost every second completed registered clinical trial on pediatric ED remains
175 unpublished, making results from 1644 enrolled study patients unavailable for clinical
176 decision making. Given the high prevalence of ED and its potentially serious
177 manifestations, this significant publication bias is both surprising and unsatisfying.
178 This lack of study results may directly influence clinical practice. An illustrative example
179 is the use of dexmedetomidine. Two published studies could show a reduction of
180 incidence and degree of ED following premedication with intranasal dexmedetomidine
181 ^{9 10}. However, dexmedetomidine, like most potent sedatives, causes an unpleasant
182 burning sensation when applied intranasally ¹¹. Oral application might therefore be a
183 better choice for anxious children. One recent study showed that 1 µg per kg oral
184 dexmedetomidine for premedication provided satisfactory sedation levels, but was not
185 effective in preventing ED ¹². On the other hand, we identified an unpublished
186 registered trial (NCT03357718 ¹³) that used 2 µg/kg, so it is not known whether oral
187 dexmedetomidine at higher doses might be as effective as intranasal application. For
188 three of the 19 unpublished studies, preliminary results are available at
189 ClinicalTrials.gov, and all three studies compared dexmedetomidine to placebo.
190 However, their preliminary results are as conflicting as the published ones: no positive
191 effects of intramuscular (NCT01535287 ¹⁴) and intravenous (NCT01901588 ¹⁵)
192 dexmedetomidine, respectively, but reduction of ED when 8-fold higher intravenous
193 doses had been used (NCT00857727 ¹⁶). Another unpublished study (NCT03171740
194 ¹⁷) compared premedication with intranasal dexmedetomidine to oral midazolam. Intra-
195 or postoperative dexmedetomidine application was investigated in five registered trials
196 (NCT01901588 ¹⁵, NCT03779282 ¹⁸, NCT00857727 ¹⁶, NCT01895023 ¹⁹,
197 NCT01535287 ¹⁴) the results of which are not available (yet) to the public. Especially

198 with regard to different doses and potential cardiocirculatory side-effects of intravenous
199 dexmedetomidine, the data of these 482 patients would be very interesting.

200 Similar considerations can be made for several study topics summarized in table 2.
201 Minimizing pain with intraoperative Fentanyl given at a mean dose of 2.5 µg/kg at the
202 end of surgery reduced the incidence of ED in a study by Cohen et al. ²⁰. However, in
203 the context of postoperative delirium in the PICU, we could recently show that fentanyl
204 increases the risk for delirium in a dose-dependent way and that this could probably
205 be attributed to substance-specific anticholinergic effects ²¹. Therefore, it would be very
206 interesting to see the results of the 322 patients from the three unpublished registered
207 trials (NCT02753725 ²², NCT03010540 ²³, NCT03062488 ²⁴) on intraoperative fentanyl
208 given at different doses.

209 Unfortunately, the low publication rate for studies on ED that we found in our analysis
210 is in line with other published observations. Anderson et al. recently reported that only
211 38.3% of all completed or prematurely terminated trials registered at ClinicalTrials.gov
212 were published ²⁵, and we came to similar conclusions when testing for publication
213 bias in fields as diverse as pediatric liver transplantation ²⁶ or autism ²⁷. Publication of
214 the results gathered in clinical trials involving human subjects is considered an ethical
215 imperative ²⁸. In 2007 it became a legal obligation in the U.S. to register all clinical trials
216 in advance and publish its results within 12 months of completion ⁸. Interestingly,
217 despite this federal law, the US was the country of investigation found to have the
218 highest rate of unpublished studies. Timely publication of the results is another issue
219 that we investigated in our study. Only 9 of the 24 published studies were published
220 within 12 months of completion, and we did not observe a trend to shorter publication
221 intervals during recent years.

222

223 Limitations

1
2
3 224 Our study has several limitations. First, we only analyzed clinical trials that were
4
5 225 registered either at ClinicalTrials.gov or ClinicalTrialsRegister.eu. Therefore, some
6
7 226 studies registered in smaller national registers may have been missed. Second, our
8
9 227 analysis relies on the accuracy of data input in the respective register. Third, we can
10
11 228 only speculate about the reasons why half of the investigators chose not to publish
12
13 229 their results, as we did not receive respective information after contacting them directly.
14
15 230 Last, it is likely that some of the recently completed studies will be published eventually,
16
17 231 but still considerably later than the 12 months warranted by the FDAAA.
18
19
20
21
22

232

233 Conclusion

234 There is a distinct publication gap in clinical research in pediatric ED. Although this
25
26 235 does not call into question the results of published studies, it should raise awareness
27
28 236 that many aspects of the current treatment options are not exactly known. Larger
29
30 237 numbers of published trials are immensely helpful to either support or challenge
31
32 238 existing data which would further improve clinical practice. In addition, timely
33
34 239 publication of study results helps to improve patient care and avoids unnecessary
35
36 240 exposure to research, in particular, if a similar research question is being investigated
37
38 241 repeatedly due to a lack of transparency.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 242 ***Authors' contributions***
4

5 243 Substantial contributions to the conception or design of the work; or the acquisition,
6
7 244 analysis, or interpretation of data for the work: JM, MR
8
9

10 245
11
12 246 Drafting the work or revising it critically for important intellectual content: JM, MR
13
14

15 247
16
17 248 Final approval of the version to be published: JM, MR
18
19

20 249
21 250 Agreement to be accountable for all aspects of the work in ensuring that questions
22
23 251 related to the accuracy or integrity of any part of the work are appropriately investigated
24
25 252 and resolved: JM, MR
26
27

28 253
29
30 254 ***Data sharing statement***
31

32 255 All relevant data are in the manuscript.
33
34

35 256
36
37 257 ***Acknowledgement***
38

39 258 We thank Lorna Stimson, PhD, for language editing.
40
41

42 259
43
44 260 ***Competing interests statement***
45

46 261 JM and MR report no conflict of interest.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

262 **References**

1. Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. *Anesthesiology* 2004;100(5):1138-45.
2. Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. *Anesth Analg* 2004;99(6):1648-54, table of contents. doi: 10.1213/01.ANE.0000136471.36680.97
3. Dahmani S, Delivet H, Hilly J. Emergence delirium in children: an update. *Curr Opin Anaesthesiol* 2014;27(3):309-15. doi: 10.1097/ACO.0000000000000076
4. Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. *Br J Anaesth* 2017;118(3):335-43. doi: 10.1093/bja/aew477
5. Moore AD, Anghelescu DL. Emergence Delirium in Pediatric Anesthesia. *Paediatr Drugs* 2017;19(1):11-20. doi: 10.1007/s40272-016-0201-5
6. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;14(8):iii, ix-xi, 1-193. doi: 10.3310/hta14080
7. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12(12):1500-24. doi: 10.1016/j.ijso.2014.07.014
8. FDAAA. Sec. 801. Expanded clinical trial registry data bank 2007 2007. Available from: <https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82> accessed 23 Sep 2020
9. Yao Y, Qian B, Lin Y, et al. Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial. *Paediatr Anaesth* 2015;25(5):492-8. doi: 10.1111/pan.12574
10. Mukherjee A, Das A, Basunia SR, et al. Emergence agitation prevention in paediatric ambulatory surgery: A comparison between intranasal Dexmedetomidine and Clonidine. *J Res Pharm Pract* 2015;4(1):24-30. doi: 10.4103/2279-042X.150051
11. Lee Y, Kim J, Kim S, et al. Intranasal administration of dexmedetomidine (DEX) as a premedication for pediatric patients undergoing general anesthesia for dental treatment. *J Dent Anesth Pain Med* 2016;16(1):25-29. doi: 10.17245/jdapm.2016.16.1.25
12. Keles S, Kocaturk O. The Effect of Oral Dexmedetomidine Premedication on Preoperative Cooperation and Emergence Delirium in Children Undergoing Dental Procedures. *Biomed Res Int* 2017;2017:6742183. doi: 10.1155/2017/6742183
13. NCT03357718. Available from: <https://ClinicalTrials.gov/show/NCT03357718> accessed 23 Sep 2020.
14. NCT01535287. Available from: <https://ClinicalTrials.gov/show/NCT01535287> accessed 23 Sep 2020.
15. NCT01901588. Available from: <https://ClinicalTrials.gov/show/NCT01901588> accessed 23 Sep 2020.
16. NCT00857727. Available from: <https://ClinicalTrials.gov/show/NCT00857727> accessed 23 Sep 2020.
17. NCT03171740. Available from: <https://ClinicalTrials.gov/show/NCT03171740> accessed 23 Sep 2020.
18. NCT03779282. Available from: <https://ClinicalTrials.gov/show/NCT03779282> accessed 23 Sep 2020.
19. NCT01895023. Available from: <https://ClinicalTrials.gov/show/NCT01895023> accessed 23 Sep 2020.

- 1
2
3 310 20. Cohen IT, Hannallah RS, Hummer KA. The incidence of emergence agitation associated
4 311 with desflurane anesthesia in children is reduced by fentanyl. *Anesth Analg*
5 312 2001;93(1):88-91. doi: 10.1097/00000539-200107000-00019
6 313
7 314 21. Meyburg J, Dill ML, von Haken R, et al. Risk Factors for the Development of Postoperative
8 315 Delirium in Pediatric Intensive Care Patients. *Pediatr Crit Care Med* 2018;19(10):e514-
9 316 e21.
10 316 22. NCT02753725. Available from: <https://ClinicalTrials.gov/show/NCT02753725> accessed
11 317 23 Sep 2020.
12 318 23. NCT03010540. Available from: <https://ClinicalTrials.gov/show/NCT03010540> accessed
13 319 23 Sep 2020.
14 320 24. NCT03062488. Available from: <https://ClinicalTrials.gov/show/NCT03062488> accessed
15 321 23 Sep 2020.
16 322 25. Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at
17 323 ClinicalTrials.gov. *N Engl J Med* 2015;372(11):1031-9. doi: 10.1056/NEJMsa1409364
18 324 26. Breil T, Wenning D, Teufel U, et al. An Assessment of Publication Status of Pediatric Liver
19 325 Transplantation Studies. *PLoS One* 2016;11(12):e0168251. doi:
20 326 10.1371/journal.pone.0168251
21 327 27. Mechler K, Hoffmann GF, Dittmann RW, et al. Defining the hidden evidence in autism
22 328 research. Forty per cent of rigorously designed clinical trials remain unpublished - a
23 329 cross-sectional analysis. *Int J Methods Psychiatr Res* 2017;26(4) doi: 10.1002/mpr.1546
24 330 28. Pearn J. Publication: an ethical imperative. *BMJ* 1995;310(6990):1313-5. doi:
25 331 10.1136/bmj.310.6990.1313
26 332
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 333 **Figure legends**
4

5 334
6

7 335 Figure 1: Flowsheet: details of the study selection process
8
9

10 336 Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of
11
12
13 337 completion
14
15

16 338 Figure 3: Distribution of patient count stratified by publication status and year
17
18

19 339 Figure 4: Time to publication (time between completion of the trial and publication
20
21
22 340 of results) in months by year of completion
23
24

25 341 "FDAAA" = timeline mandated by the U.S. Food and Drug Administration
26
27

28 342 Amendments Act of 2007
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Published (n=25) and unpublished (n=19) completed studies on pediatric emergence delirium by country

Countries	Published studies (n)	Unpublished studies (n)
Belgium	2	0
Brasil	0	1
Canada	1	0
China	0	2
Egypt	1	0
Greece	1	0
India	1	1
Italy	1	0
Kenya	0	1
South Korea	8	4
Thailand	2	1
Turkey	3	2
United States	4	8

Table 2: Publication status of studies registered as completed on ClinicalTrials.gov and ClinicalTrialsRegister.eu involving children with emergence delirium

Topic of investigation	Overall number of studies	Number and percentage of published studies	Number of patients enrolled in unpublished studies
Dexmedetomidin	13	5 (38%)	598
Diagnostic criteria	6	2 (33%)	326
Non-pharmacological interventions	5	4 (80%)	100
Opioids	5	2 (40%)	322
Other drugs	5	4 (80%)	60
Propofol	4	3 (75%)	108
Volatile anesthetics	3	1 (33%)	152
Midazolam	3	3 (100%)	0




Figure 1: Flowsheet: details of the study selection process

190x275mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Distribution of published (n=24) and unpublished (n=20) trials by year of completion

296x209mm (300 x 300 DPI)




Figure 3: Distribution of patient count stratified by publication status and year

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4: Time to publication (time between completion of the trial and publication of results) in months by year of completion
"FDAAA" = timeline mandated by the U.S. Food and Drug Administration Amendments Act of 2007

296x209mm (300 x 300 DPI)

Supplemental Table: Published and unpublished completed clinical studies in pediatric emergence delirium (Studies were completed before September 1st 2018, close of database was September 1st 2019)

Trial number	published	Date of completion [DD.MM.YY]	Date of publication [DD.MM.YY]	Time to Publication [months]	Study Title	Intervention	Patients enrolled [n]	Country
NCT00932685 ¹	yes	01.07.07	01.03.16	104	Does Distraction With a Hand Held Video Game Reduce Preoperative and Emergence Anxiety in Children?	Drug: Midazolam Device: Game Boy	119	United States
NCT00468052 ²	yes	01.05.08	01.10.10	29	Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy	Drug: Dexmedetomidine Drug: Fentanyl	122	United States
NCT01096797 ³	yes	01.03.10	01.05.15	62	Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children	Drug: Sevoflurane	150	Italy
NCT00990769 ⁴	yes	01.09.10	01.04.16	67	The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children	Other: Depth of anesthesia	40	United States
NCT01440114 ⁵	yes	01.07.11	01.12.13	29	The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia	Drug: Fentanyl Drug: NSS	144	Thailand
NCT00885443 ⁶	yes	01.08.11	01.04.13	20	Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanyl Versus Inhalational Sevoflurane Anesthesia	Drug: Propofol Drug: Sevoflurane	112	Kanada
NCT01506622 ⁷	yes	01.12.11	01.02.13	14	Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia	Drug: Propofol Drug: Fentanyl Drug: Saline	222	South Korea
NCT01512355 ⁸	yes	01.03.12	01.03.14	24	The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery	Drug: Dexmedetomidine	88	South Korea
NCT01235143 ⁹	yes	01.08.12	01.11.13	15	Emergence Agitation Between	Drug: Desflurane	136	Thailand

					Sevoflurane and Desflurane in Pediatric	Drug: Sevoflurane		
NCT02022488 ¹⁰	yes	01.08.12	01.09.14	25	Sevoflurane Induced Emergence Agitation	Drug: Midazolam Drug: Alfentanil Drug: Ketamine	78	Turkey
NCT01680471 ¹¹	yes	01.11.12	01.06.14	19	A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery	Drug: Midazolam 0.03mg/kg Drug: Midazolam 0.05mg/kg	90	South Korea
NCT02256358 ¹²	yes	01.01.14	01.04.16	27	Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation	Drug: Midazolam Drug: Ketamine	68	South Korea
NCT01528891 ¹³	yes	01.08.14	01.11.15	15	Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation	Drug: Dexmedetomidine	418	United States
2015-002329-20 ¹⁴	yes	31.03.16	01.12.17	20	Xenon as an adjuvant to sevoflurane anaesthesia in children younger than four, undergoing interventional or diagnostic cardiac catheterization: a pilot study	Drug: Xenon	40	Belgium
NCT02428283 ¹⁵	yes	01.11.16	01.07.17	8	Scalp Nerve Block on Emergence Agitation	Drug: Ropivacaine Drug: Remifentanil Drug: Sevoflurane	44	South Korea
NCT02997124 ¹⁶	yes	01.11.16	01.10.18	23	Transversus Abdominis Plane Block in Iliac Crest harvest-is it Beneficial?	Procedure: local infiltration and TAP block Procedure: local infiltration only	143	India
NCT03174678 ¹⁷	yes	01.05.17	01.08.17	3	Dexmedetomidine Premedication in Children	Drug: Dexmedetomidine	100	Turkey
NCT03131375 ¹⁸	yes	01.07.17	01.07.18	12	Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia	Drug: Dexmedetomidine Drug: Normal saline Device: Bispectral index Device: Train of four ratio	60	Greece
NCT03197753 ¹⁹	yes	01.08.17	01.08.18	12	Postoperative Discomfort After Dental General Anesthesia	Device: Laryngeal mask airway Device: Nasotracheal intubation	70	Turkey
NCT02955680 ²⁰	yes	01.09.17	01.08.18	11	Recorded Maternal Voice on the Emergence of General Anesthesia on Pediatric Patients	Procedure: recorded maternal voice Procedure: recorded stranger's voice	66	South Korea

NCT03172182 ²¹	yes	01.10.17	01.01.19	15	Perioperative Effects of Operating Room Virtual Tour	Behavioral: 360-degree VR video tour	86	South Korea
2014-002510-23 ²²	yes	21.12.17	01.08.18	7	Xenon as an adjuvant to sevoflurane anaesthesia in children undergoing interventional or diagnostic catheterization: a randomized controlled clinical trial	Drug: Xenon	40	Belgium
NCT03179293 ²³	yes	01.06.18	06.03.19	9	Transition to Propofol After Sevoflurane Anaesthesia to Prevent Emergence Agitation	Drug: Propofol Drug: Saline	70	Egypt
NCT03807011 ²⁴	yes	01.10.18	01.08.18		Emergence Agitation in Pediatric Strabismus Surgery	Drug: Fentanyl Drug: Remifentanyl	90	South Korea
NCT00535613 ²⁵	no	01.12.10			Propofol in Emergence Agitation	Drug: Propofol	100	United States
NCT00857727 ²⁶	no	01.12.11			Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children	Drug: Dexmedetomidine Drug: Saline	33	United States
NCT01748630 ²⁷	no	01.10.12			Effects of Dexmedetomidine on the Postoperative Experience in Children	Drug: dexmedetomidine Drug: Midazolam Drug: Fentanyl	42	Turkey
NCT01535287 ²⁸	no	01.10.13			Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia	Drug: Dexmedetomidine	140	United States
NCT03358069 ²⁹	no	01.06.14			Does Emergence Time Relate With Emergence Agitation in Pediatric Patients?	Diagnostic Test: Emergence agitation scale	91	Thailand
NCT01895023 ³⁰	no	01.08.14			Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children	Drug: Dexmedetomidine Drug: Midazolam Drug: Saline	156	China
NCT02489734 ³¹	no	01.09.15			Post Extubation Delirium and End-tidal Sevoflurane Concentration	Drug: Sevoflurane	92	China
NCT02980549 ³²	no	01.01.16			How Common Are Sleep Disorders and Problems With Emergence From Anesthesia in Surgical Patients	Diagnostic Test: children's sleep habits questionnaire	100	United States
NCT02521259 ³³	no	01.04.16			Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery	Device: BIS	68	South Korea
NCT01901588 ³⁴	no	01.05.16			Efficacy of Single-Shot	Drug: Dexmedetomidine	63	United

					Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery			States
NCT02753725 ³⁵	no	01.07.16			Effect of Fentanyl on Emergence Delirium (ED) on Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital (KNH)	Drug: Fentanyl Drug: Saline	110	Kenya
NCT02383004 ³⁶	no	01.11.16			Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement	Other: Acupuncture	100	United States
NCT03010540 ³⁷	no	01.12.16			Effect Of Combination of Morphine+Fentanyl on Emergence Delirium in Patients of Cleft Lip and Palate Repair	Drug: Morphine plus Fentanyl Drug: Fentanyl	70	India
NCT03134547 ³⁸	no	01.02.17			A Comparison of Emergence Agitation by Sevoflurane for Intraoperative Sedation Associated With Caudal Block	Drug: low dose Sevoflurane Drug: high dose Sevoflurane	40	South Korea
NCT03357718 ³⁹	no	01.06.17			Oral Dexmedetomidine vs Midazolam For Premedication	Drug: Precedex Drug: Midazolam	52	Turkey
NCT03332407 ⁴⁰	no	01.09.17			Does Preoperative Sleep Quality Affect the Postoperative Emergence Delirium in Children Undergoing Strabismus Surgery	Other: Sleep Quality	67	South Korea
NCT03132701 ⁴¹	no	01.12.17			The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children	Drug: Magnesium Drug: Saline	66	South Korea
NCT03171740 ⁴²	no	01.01.18			Premedication With Intranasal Dexmedetomidine or Midazolam for Prevention of Emergence Agitation in Children	Drug: Dexmedetomidine Drug: Midazolam Drug: Oral saline Drug: Nasal saline	22	Brasil
NCT03062488 ⁴³	no	01.07.18			Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery	Drug: IV acetaminophen Drug: Fentanyl Drug: PO acetaminophen	142	United States
NCT03779282 ⁴⁴	no	01.09.18			KETODEX for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery	Drug: Dexmedetomidine	90	United States

Supplemental Table. List of published (n=24) and unpublished (n=20) trials in pediatric emergence delirium. Close of database was September 1st 2019.

References

1. <https://ClinicalTrials.gov/show/NCT00932685> (accessed 23 Sep 2020)
2. <https://ClinicalTrials.gov/show/NCT00468052> (accessed 23 Sep 2020)
3. <https://ClinicalTrials.gov/show/NCT01096797> (accessed 23 Sep 2020)
4. <https://ClinicalTrials.gov/show/NCT00990769> (accessed 23 Sep 2020)
5. <https://ClinicalTrials.gov/show/NCT01440114> (accessed 23 Sep 2020)
6. <https://ClinicalTrials.gov/show/NCT00885443> (accessed 23 Sep 2020)
7. <https://ClinicalTrials.gov/show/NCT01506622> (accessed 23 Sep 2020)
8. <https://ClinicalTrials.gov/show/NCT01512355> (accessed 23 Sep 2020)
9. <https://ClinicalTrials.gov/show/NCT01235143> (accessed 23 Sep 2020)
10. <https://ClinicalTrials.gov/show/NCT02022488> (accessed 23 Sep 2020)
11. <https://ClinicalTrials.gov/show/NCT01680471> (accessed 23 Sep 2020)
12. <https://ClinicalTrials.gov/show/NCT02256358> (accessed 23 Sep 2020)
13. <https://ClinicalTrials.gov/show/NCT01528891> (accessed 23 Sep 2020)
14. <https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002329-20/BE> (accessed 23 Sep 2020)
15. <https://ClinicalTrials.gov/show/NCT02428283> (accessed 23 Sep 2020)
16. <https://ClinicalTrials.gov/show/NCT02997124> (accessed 23 Sep 2020)
17. <https://ClinicalTrials.gov/show/NCT03174678> (accessed 23 Sep 2020)
18. <https://ClinicalTrials.gov/show/NCT03131375> (accessed 23 Sep 2020)
19. <https://ClinicalTrials.gov/show/NCT03197753> (accessed 23 Sep 2020)
20. <https://ClinicalTrials.gov/show/NCT02955680> (accessed 23 Sep 2020)
21. <https://ClinicalTrials.gov/show/NCT03172182> (accessed 23 Sep 2020)
22. <https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002510-23/BE> (accessed 23 Sep 2020)
23. <https://ClinicalTrials.gov/show/NCT03179293> (accessed 23 Sep 2020)
24. <https://ClinicalTrials.gov/show/NCT03807011> (accessed 23 Sep 2020)

- 1
- 2 25. <https://ClinicalTrials.gov/show/NCT00535613> (accessed 23 Sep 2020)
- 3 26. <https://ClinicalTrials.gov/show/NCT00857727> (accessed 23 Sep 2020)
- 4 27. <https://ClinicalTrials.gov/show/NCT01748630> (accessed 23 Sep 2020)
- 5 28. <https://ClinicalTrials.gov/show/NCT01535287> (accessed 23 Sep 2020)
- 6 29. <https://ClinicalTrials.gov/show/NCT03358069> (accessed 23 Sep 2020)
- 7 30. <https://ClinicalTrials.gov/show/NCT01895023> (accessed 23 Sep 2020)
- 8 31. <https://ClinicalTrials.gov/show/NCT02489734> (accessed 23 Sep 2020)
- 9 32. <https://ClinicalTrials.gov/show/NCT02980549> (accessed 23 Sep 2020)
- 10 33. <https://ClinicalTrials.gov/show/NCT02521259> (accessed 23 Sep 2020)
- 11 34. <https://ClinicalTrials.gov/show/NCT01901588> (accessed 23 Sep 2020)
- 12 35. <https://ClinicalTrials.gov/show/NCT02753725> (accessed 23 Sep 2020)
- 13 36. <https://ClinicalTrials.gov/show/NCT02383004> (accessed 23 Sep 2020)
- 14 37. <https://ClinicalTrials.gov/show/NCT03010540> (accessed 23 Sep 2020)
- 15 38. <https://ClinicalTrials.gov/show/NCT03134547> (accessed 23 Sep 2020)
- 16 39. <https://ClinicalTrials.gov/show/NCT03357718> (accessed 23 Sep 2020)
- 17 40. <https://ClinicalTrials.gov/show/NCT03332407> (accessed 23 Sep 2020)
- 18 41. <https://ClinicalTrials.gov/show/NCT03132701> (accessed 23 Sep 2020)
- 19 42. <https://ClinicalTrials.gov/show/NCT03171740> (accessed 23 Sep 2020)
- 20 43. <https://ClinicalTrials.gov/show/NCT03062488> (accessed 23 Sep 2020)
- 21 44. <https://ClinicalTrials.gov/show/NCT03779282> (accessed 23 Sep 2020)
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title, Page 2, line 33
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2, lines 27-47
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4, line 63 to page 5 line 89
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 2, lines 27-33 Page 3, line 87 to page 5 line 89
Methods			
Study design	4	Present key elements of study design early in the paper	Page 2 line 33, page 5 line 89
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6 lines 91-108
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Page 6 lines 110 to page 7 line 118
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 7 lines 120-138
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6 line 101 to page 7 line 138
Bias	9	Describe any efforts to address potential sources of bias	Page 6 line 114 to page 7 line 118
Study size	10	Explain how the study size was arrived at	Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 7 line 120 - 138
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 7 lines 136-138

		(b) Describe any methods used to examine subgroups and interactions	No applicable
		(c) Explain how missing data were addressed	Page 7 line 136
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Page 7 line 138
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 8, lines 144-154, Figure 1
		(b) Give reasons for non-participation at each stage	Page 8 line 151 -154
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables 1 and 2, Figures 2 and 3
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Tables 1 and 2, Figures 2,3, and 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Not applicable
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 10 lines 173-177
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11 line 223 to page 12 line 231
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 12 lines 209 to 221
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 12 lines 233 to 241
Other information			

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 3 lines 59-61
---------	----	---	--------------------

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.